The European Medicines Agency (EMA) has finalized a revised guideline on anticancer drug development, placing additional emphasis on the inclusion of elderly patients in clinical trials. The elderly and frail constitute a vulnerable group of patients rarely included in conventional studies of oncology drugs, for which they are the most likely recipients, the agency said.
Clinical Trials Advisor